

**Subject:** Multiple Sclerosis Treatment Testimonial - Pass on to anyone you know with MS

**From:** "Esperanza" <esperanzapeptide@btinternet.com>

**Date:** Fri, 28 Jul 2006 11:50:17 +0100

**To:** "Esperanza" <esperanzapeptide@btinternet.com>

**X-Account-Key:** account6

**X-UIDL:** APmyo0IAACiKRRKJfGAHqXVnwXHM

**X-Mozilla-Status:** 0003

**X-Mozilla-Status2:** 10000000

**X-Apparently-To:** eriksmithx@yahoo.com via 66.163.178.249; Wed, 28 Jun 2006 03:51:03 -0700

**X-Originating-IP:** [217.12.12.138]

**Authentication-Results:** mta237.mail.mud.yahoo.com from=btinternet.com; domainkeys=neutral (no sig)

**Received:** from 217.12.12.138 (HELO smtp801.mail.ukl.yahoo.com) (217.12.12.138) by mta237.mail.mud.yahoo.com with SMTP; Wed, 28 Jun 2006 03:51:03 -0700

**Received:** (qmail 46348 invoked from network); 28 Jun 2006 10:50:59 -0000

**Received:** from unknown (HELO default5711f29) (esperanzapeptide@btinternet.com@81.158.38.55 with login) by smtp801.mail.ukl.yahoo.com with SMTP; 28 Jun 2006 10:50:36 -0000

**Message-ID:** <033e01c6b233\$9e8bdc00\$37269e51@default5711f29>

**MIME-Version:** 1.0

**Content-Type:** multipart/related; type="multipart/alternative"; boundary="-----\_NextPart\_000\_0308\_01C6B23B.FEF1C570"

**X-Priority:** 3

**X-MSMail-Priority:** Normal

**X-Mailer:** Microsoft Outlook Express 6.00.2900.2869

**X-MimeOLE:** Produced By Microsoft MimeOLE V6.00.2900.2869



**Multiple Sclerosis**

# Treatment Testimonial

**Please feel free to pass this on to anyone that may be interested in the results of this treatment!**

---

**NEW** - See the new PowerPoint Presentation relating to the technology of our Peptide ... [see link below](#)

---

## Multiple Sclerosis Testimonial:



### **It Was Peptide Or Nothing - First Peptide Birth!**

I was diagnosed with Multiple Sclerosis in 2001 at age 27. I was a dancer and a theatre actress. I, unknowingly, started having MS symptoms at age 19. I was so physical with theatre and dance that "would-be" symptoms got blown off as pulled muscles, ligaments, nerves, etc. I would be at the top of my game and would become

completely exhausted. I would take about three weeks off from life, and would go and see psychiatrists and counsellors. I felt something was going on in my head. To my dismay, they would agree with me and tell me that I was bipolar, schitzo, and manic. MS had just not manifested physically yet. From this point my journey became ever so slowly worse. I finally got properly diagnosed and treated. The medications that were to make me better, made me, what I considered ... worse. My hair fell out. I hallucinated, insanity actually started to set in, and I could not understand why the meds did not protect me from exacerbations. By the time I made it to Freeport, I was walking with a cane and human assistance, and a wheel chair if there was one around.

It was Peptide or nothing. I had tried everything; I was so desperate I even tried some unconventional tactics.

The first time that David dosed me was with the puffer, no injection. He told me to get up and walk to the wall. I did! Now, I have to give an explanation of what this means. For me to even stand up from a sitting position, I would first have to mentally tell my body piece by piece what to expect and what to do. After I had made it through the instruction, then I would have to wait for the uncontrollable shaking in my legs to stop, then I would have to scout out things that I could reach out and fall into. Go through the whole process again to reach the next point just to get across a room. Now let me say it again. David said "Get up & walk to the wall." Instantly, without thinking, I did! Then, since I was so good at standing AND walking without thinking, he wanted me to again stand with my feet together and my eyes closed. The first time, prior peptide, I could do it for about 3 seconds. This time I did it for 3 minutes plus.

For as long as I live, I will never forget David saying, "Welcome Back!" It was as if I had been in a semi-state of unconsciousness for years. Suzanne asked me how did it feel. It was if someone had taken off huge chains that had been wrapped around my feet, legs, arms, hands, and shoulders. It was almost like sighing after holding my

breath for years.

Even more remarkable, I had a peptide baby. Before, any other medications that I was taking to treat my MS, I was told not to conceive a child without being off the medication for at least a year. I took my peptide through my whole pregnancy and while I was nursing. I also did not or have not had even a whisper of MS before, during, or after. To be quite honest, since I have been on Esperanza Peptide, I have not had an exacerbation in over two years, which is over half of my MS life.

Gillie Daugherty  
Kentucky, USA



**NEW - PowerPoint Presentation:**

<http://www.esperanzapeptide.net/power-point/pharma-tech-science.ppt>

**For more details please feel free to click on any of the links below:**

Main Page: <http://www.esperanzapeptide.net>

Treatment Program: <http://www.esperanzapeptide.net/treatment-program.php>

Questions & Answers: <http://www.esperanzapeptide.net/questions-answers.php>

Travel To Our Clinic: <http://www.esperanzapeptide.net/travel.php>

Testimonials: <http://www.esperanzapeptide.net/testimonials.php>

Trial Program: <http://www.esperanzapeptide.net/trial.php>

Our Technology: <http://www.esperanzapeptide.net/technologies.php>

Executive Summary: <http://www.esperanzapeptide.net/executive-summary.php>

News & Published Studies: <http://www.esperanzapeptide.net/news.php>

**NEW - PowerPoint Presentation:**

<http://www.esperanzapeptide.net/power-point/pharma-tech-science.ppt>

---

**UNSUBSCRIBE** - This email was sent to you as an information email about the above noted treatment. Most emails in our database are obtained from referrals to us by like-minded individuals that feel that the information above will be of interest to others. If you do not wish to receive any further updates please let us know by sending this email back by clicking REPLY and inserting the word REMOVE in the subject line and we will remove your email address immediately from our database. If you know of someone that may be interested in learning more about this treatment please forward on this email on to them.

---

## Published in:



Time magazine reported in its January 16, 2001 issue that a drug derived from modified cobra venom might be tested at Canadian MS clinics as a treatment for MS in the near future.

Immunokine has been tried in 25 people with MS under non-placebo controlled conditions with initial encouraging

results. Esperanza Peptide, the Bahamas based company that makes the drug, has applied to Health Canada to test it at several Canadian MS clinics. Additional details will be provided when they become available.

The study of Immunokine was a Phase I trial. This is a short study in which both the people receiving the therapy and the study investigators know the participants are receiving active treatment. The primary outcome is to test for safety of the therapy.

The usual next step would be a Phase II trial in which participants are divided into groups. One group receives active treatment and one receives a placebo (non-active) treatment. Neither the participants nor the physicians who examine them know who is taking which treatment until the code is broken at the end of the study. This is called a double-blind, placebo controlled study. The investigators start to gather data on whether the therapy actually works while still measuring safety.

If results from the Phase II study are positive, the next stage is a Phase III trial. It is a double-blind, placebo controlled study that involves a large number of people, often at many research sites for a number of months. It collects data on safety, the effectiveness of the therapy and side effects. These data are necessary for any submission to Health Canada for evaluation of a therapy for potential approval.





## A randomized controlled study of modified cobratoxin in adrenomyeloneuropathy

H.R. Mundy, MBBS, S.J. Jones, PhD, J.C. Hobart, PhD, M.G. Hanna, PhD and P.J. Lee, MD

From the Charles Dent Metabolic Unit (Drs. Mundy and Lee), Department of Neurophysiology (Dr. Jones), and Department of Clinical Neurology and Neurorehabilitation (Dr. Hobart), National Hospital for Neurology and Neurosurgery, Queen Square; and Muscle and Neurogenetics Section (Dr. Hanna), Institute of Neurology, Queen Square, London, UK.

Address correspondence and reprint requests to Dr. Mundy, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK;

Adrenomyeloneuropathy is a peroxisomal disorder that causes demyelination, with no proven therapy. Oral modified cobratoxin was assessed in a double-blind, randomized, crossover study of eight patients. Treatment was well tolerated.

---



## **A randomized controlled study of modified cobratoxin in adrenomyeloneuropathy**

**H.R. Mundy, MBBS, S.J. Jones, PhD, J.C. Hobart, PhD, M.G. Hanna, PhD and P.J. Lee, MD**

From the Charles Dent Metabolic Unit (Drs. Mundy and Lee), Department of Neurophysiology (Dr. Jones), and Department of Clinical Neurology and Neurorehabilitation (Dr. Hobart), National Hospital for Neurology and Neurosurgery, Queen Square; and Muscle and Neurogenetics Section (Dr. Hanna), Institute of Neurology, Queen Square, London, UK.

Address correspondence and reprint requests to Dr. Mundy, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK;

Adrenomyeloneuropathy is a peroxisomal disorder that causes demyelination, with no proven therapy. Oral modified cobratoxin was assessed in a double-blind, randomized, crossover study of eight patients. Treatment was well tolerated.

---



## **A BRAVE mum, (given only months to live) is celebrating seeing another year with her family.**

Debbie Christie, 34, was diagnosed with motor neurone disease in December 2002 and given a maximum of 15 months to live.

By June 2004 she was in constant pain and could barely talk.

Her husband Colin and their children Lauren, 13, and Colin, 17, began preparing themselves for her death.

But in July Debbie flew to the Bahamas for an experimental drug treatment that has transformed her life.

Now she's no longer in pain and can do most things for herself.

And, above all, she is looking forward to the future with her family.

Debbie said: "I didn't think I would see 2005 and I know I was not expected to be here at Christmas.

"But in the last six months I've felt better than I have in years.

"I know this drug is not going to stop my illness, but it's slowing it down.

"It's giving me more time with my family and every extra day is fantastic.

"I'm taking it day by day, but I do hope I'll be celebrating Hogmanay in 2006."

Debbie, of Girdle Toll in Irvine, flew to the Bahamas in July after generous Evening Times readers helped raise £8000 for the trip and treatment.

She spent a week being injected three times daily with peptide, a drug derived from cobra venom and not yet licensed in the UK.

After just one day of treatment Debbie's pain lessened and she was able to move her hips for the first time in months.

By the last day of the course she could walk without any help.

Debbie said: "For almost two years every month brought some new problem. I was just getting worse and worse.

"I would just stay in bed all day because I was so ill.

"Now I only go to bed at night. The last six months are the best I've experienced for years.

"It was my daughter's birthday in December and my son's on January 1, and I was really glad to be here with them. Last year there was a good chance that I wouldn't have been."

"I'm just taking life one day at a time. Every extra day I spend with my family is fantastic.



## **TERMINALLY ILL MOTHER PRAISES EXPERIMENTAL DRUG**

A terminally ill mother who flew to the Bahamas to receive a radical new treatment for her degenerative neurological condition has


claimed the drug - which is experimental in the UK - has transformed her life.

Debbie Christie, 34, was diagnosed with motor neurone disease (MND) last December and told that she could expect to live for just a few months.

Before flying to the Caribbean for the treatment involving a drug derived from cobra venom, Mrs Christie was in constant pain, could not lift her head and talking caused her jaw to lock.

However, after one day of the new treatment the pain lessened and she was able to move her hips for the first time in months, she said.

---



Daily Biotech Update... [www.genengnews.com](http://www.genengnews.com)


# GENETIC ENGINEERING

GEN Celebrates its 20th Anniversary in 2000 NEWS

## Delivery of Peptide Therapeutics

Companies Explore Inhalable, Spray and Lipid Particle Technologies

Neil McGinnis, Ph.D.



The diagram illustrates the process of peptide delivery. It shows a cross-section of a lung capillary. On the left, a blue sphere labeled 'Aerosol Particle' is shown in the 'Air' space. Below it, 'Solubilized Micromolecules' are shown entering a 'Lung Cell'. From the lung cell, the molecules move into a 'Capillary Cell' and finally into the 'Blood'.

Peptide Therapeutics Systems, Inc. (PTSI) is a leading provider of peptide-based therapies for a wide range of diseases. The company's products are designed to be delivered via inhalation, spray, or lipid particles. This allows for direct delivery to the site of action, bypassing the digestive system and first-pass metabolism. The resulting higher bioavailability and lower systemic side effects make these therapies an attractive alternative to traditional oral or intravenous treatments.

PTSI's products are currently in clinical trials for a variety of conditions, including chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company's proprietary delivery technologies are designed to protect the peptide from degradation and ensure its efficient uptake by target cells.

For more information on the latest in peptide therapeutics, visit [www.ptsi.com](http://www.ptsi.com).

# SOUTH FLORIDA THE BUSINESS JOURNAL



# SCIENTIFIC AMERICAN.COM



# Men'sHealth





|                 |  |
|-----------------|--|
| <b>Part 1.3</b> | <b>Content-Type:</b> text/plain<br><b>Content-Encoding:</b> 7bit |
|-----------------|--|

---

|                 |  |
|-----------------|--|
| <b>Part 1.5</b> | <b>Content-Type:</b> text/plain<br><b>Content-Encoding:</b> 7bit |
|-----------------|--|

---

|                 |  |
|-----------------|--|
| <b>Part 1.7</b> | <b>Content-Type:</b> text/plain<br><b>Content-Encoding:</b> 7bit |
|-----------------|--|

---

|                 |  |
|-----------------|--|
| <b>Part 1.9</b> | <b>Content-Type:</b> text/plain<br><b>Content-Encoding:</b> 7bit |
|-----------------|--|

---

|                  |  |
|------------------|--|
| <b>Part 1.11</b> | <b>Content-Type:</b> text/plain<br><b>Content-Encoding:</b> 7bit |
|------------------|--|

---

|                  |                                 |
|------------------|---------------------------------|
| <b>Part 1.13</b> | <b>Content-Type:</b> text/plain |
|------------------|---------------------------------|

**Content-Encoding:** 7bit

**Part 1.15**

**Content-Type:** text/plain

**Content-Encoding:** 7bit

**Part 1.17**

**Content-Type:** text/plain

**Content-Encoding:** 7bit

**Part 1.19**

**Content-Type:** text/plain

**Content-Encoding:** 7bit

**Part 1.21**

**Content-Type:** text/plain

**Content-Encoding:** 7bit

**Part 1.23**

**Content-Type:** text/plain

**Content-Encoding:** 7bit

**Part 1.25**

**Content-Type:** text/plain

**Content-Encoding:** 7bit

**Part 1.27**

**Content-Type:** text/plain

**Content-Encoding:** 7bit

**Part 1.29**

**Content-Type:** text/plain

**Content-Encoding:** 7bit

**Part 1.31**

**Content-Type:** text/plain

**Content-Encoding:** 7bit

**Part 1.33**

**Content-Type:** text/plain

**Content-Encoding:** 7bit

**Part 1.35**

**Content-Type:** text/plain

**Content-Encoding:** 7bit

**Part 1.37**

**Content-Type:** text/plain

**Content-Encoding:** 7bit

**Part 1.39**

**Content-Type:** text/plain

**Content-Encoding:** 7bit

**Part 1.41**

**Content-Type:** text/plain

**Content-Encoding:** 7bit

**Part 1.43**

**Content-Type:** text/plain

**Content-Encoding:** 7bit

**Part 1.45**

**Content-Type:** text/plain

**Content-Encoding:** 7bit

**Part 1.47**

**Content-Type:** text/plain

**Content-Encoding:** 7bit

**Part 1.49**

**Content-Type:** text/plain

**Content-Encoding:** 7bit